GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (STU:ASZ1) » Definitions » Additional Paid-In Capital

Alimera Sciences (STU:ASZ1) Additional Paid-In Capital : €426.26 Mil(As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Alimera Sciences Additional Paid-In Capital?


Alimera Sciences's quarterly additional paid-in capital declined from Sep. 2023 (€432.54 Mil) to Dec. 2023 (€424.06 Mil) but then increased from Dec. 2023 (€424.06 Mil) to Mar. 2024 (€426.26 Mil).

Alimera Sciences's annual additional paid-in capital increased from Dec. 2021 (€333.85 Mil) to Dec. 2022 (€357.06 Mil) and increased from Dec. 2022 (€357.06 Mil) to Dec. 2023 (€424.06 Mil).

Alimera Sciences Additional Paid-In Capital Historical Data

The historical data trend for Alimera Sciences's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alimera Sciences Additional Paid-In Capital Chart

Alimera Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 315.11 300.71 333.85 357.06 424.06

Alimera Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 353.19 357.18 432.54 424.06 426.26

Alimera Sciences Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Alimera Sciences Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Alimera Sciences's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Alimera Sciences (STU:ASZ1) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (STU:ASZ1) » Definitions » Additional Paid-In Capital
Comparable Companies
ZOM LFCR TKNO OPTN ELTP RGC AQST EBS ESPR ETON ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 XSWX:SDZ VTRS NBIX
Traded in Other Exchanges
ALIM:USA ASZ1:Germany
Address
6310 Town Square, Suite 400, Alpharetta, GA, USA, 30005
Website
https://www.alimerasciences.com
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.

Alimera Sciences (STU:ASZ1) Headlines

No Headlines